Cartiva, Inc. is an evidence-based medical device company with the first and only FDA approved synthetic cartilage implant for the treatment of osteoarthritis. Cartiva’s synthetic cartilage is made of a biomedical polymer that mimics natural cartilage. The durable material is proven to withstand the repetitive compressive loads that occur clinically in the great toe joint, while the low coefficient of friction aids in smooth joint articulation and mobility. Cartiva’s implant offers patients a joint preserving alternative to fusion of the great toe with substantial pain reduction and improved range of motion and is backed by the largest and most rigorous clinical study for this condition. Cartiva is currently investigating use of its platform technology for additional indications, including near-term use in lesser metatarsal and CMC arthritis, and longer-term applications for the ankle, elbow and shoulder. Cartiva’s management team, board of directors and medical advisers are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization. Cartiva’s venture investors include New Enterprise Associates, Windham Venture Partners and Domain Associates.